Last reviewed · How we verify

Artesunate-amodiaquine + primaquine

University of Oxford · Phase 3 active Small molecule

Artesunate-amodiaquine + primaquine is a Antimalarial combination therapy Small molecule drug developed by University of Oxford. It is currently in Phase 3 development for Uncomplicated malaria (Plasmodium falciparum and other species), Prevention of malaria relapse in P. vivax and P. ovale infections.

This combination therapy kills malaria parasites through multiple mechanisms: artesunate and amodiaquine target the parasite's hemoglobin digestion and DNA replication, while primaquine eliminates dormant liver stages and gametocytes to prevent transmission and relapse.

This combination therapy kills malaria parasites through multiple mechanisms: artesunate and amodiaquine target the parasite's hemoglobin digestion and DNA replication, while primaquine eliminates dormant liver stages and gametocytes to prevent transmission and relapse. Used for Uncomplicated malaria (Plasmodium falciparum and other species), Prevention of malaria relapse in P. vivax and P. ovale infections.

At a glance

Generic nameArtesunate-amodiaquine + primaquine
SponsorUniversity of Oxford
Drug classAntimalarial combination therapy
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Artesunate is an artemisinin derivative that generates reactive oxygen species to damage parasite proteins and DNA. Amodiaquine is a quinoline antimalarial that intercalates into parasite DNA and inhibits heme polymerization. Primaquine is a 8-aminoquinoline that is particularly effective against hypnozoites (dormant forms in P. vivax and P. ovale) and sexual stages, addressing the major limitation of the artesunate-amodiaquine combination alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Artesunate-amodiaquine + primaquine

What is Artesunate-amodiaquine + primaquine?

Artesunate-amodiaquine + primaquine is a Antimalarial combination therapy drug developed by University of Oxford, indicated for Uncomplicated malaria (Plasmodium falciparum and other species), Prevention of malaria relapse in P. vivax and P. ovale infections.

How does Artesunate-amodiaquine + primaquine work?

This combination therapy kills malaria parasites through multiple mechanisms: artesunate and amodiaquine target the parasite's hemoglobin digestion and DNA replication, while primaquine eliminates dormant liver stages and gametocytes to prevent transmission and relapse.

What is Artesunate-amodiaquine + primaquine used for?

Artesunate-amodiaquine + primaquine is indicated for Uncomplicated malaria (Plasmodium falciparum and other species), Prevention of malaria relapse in P. vivax and P. ovale infections.

Who makes Artesunate-amodiaquine + primaquine?

Artesunate-amodiaquine + primaquine is developed by University of Oxford (see full University of Oxford pipeline at /company/university-of-oxford).

What drug class is Artesunate-amodiaquine + primaquine in?

Artesunate-amodiaquine + primaquine belongs to the Antimalarial combination therapy class. See all Antimalarial combination therapy drugs at /class/antimalarial-combination-therapy.

What development phase is Artesunate-amodiaquine + primaquine in?

Artesunate-amodiaquine + primaquine is in Phase 3.

What are the side effects of Artesunate-amodiaquine + primaquine?

Common side effects of Artesunate-amodiaquine + primaquine include Nausea, Vomiting, Abdominal pain, Headache, Hemolysis (in G6PD-deficient patients, primaquine-related).

Related